BP's Castrol Sale, Abivax's Biotech Surge, and B&M's Retail Struggles | Stock Movers

BP Divests Castrol Stake

• 🛢️ BP has agreed to sell a 65% majority stake in its Castrol lubricants division to Stonepeak Partners for approximately $6 billion.
• 💡 This divestment is part of BP's strategy to pivot back towards focusing on fossil fuels and away from other business areas, partly in response to pressure from activist investor Elliot.
• 📈 While BP shares saw a small uptick of 0.1% on the news, investors await the new CEO's strategy for further share price recovery.

Abivax's Remarkable Biotech Gains

• 🔬 French biotechnology company Abivax has experienced a 1,600% rally this year, making it the top performer in the stock 600 index.
• 🚀 This surge is attributed to positive trial results for its bowel disease drug.
• 🔑 Key catalysts for next year include phase 3 maintenance results for its ulcerative colitis treatment in Q2 and trial results for its Crohn's disease treatment in the second half.

B&M's Retail Challenges

• 📉 B&M is the second-worst performer in the stock 600 index, with shares falling over 56% this year and extending a previous year's decline.
• ⚠️ The discount retailer faces challenges including rising competition, increased wage costs, and reduced spending power among its core low-income customer base due to the cost of living crisis.
• ⏳ The company has cut guidance multiple times, its CFO departed after an accounting error, and the new CEO estimates a turnaround could take up to 18 months, involving strategies like cutting key food prices and reducing product offerings.